Aldeyra Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Aldeyra Therapeutics (ALDX).

Price Target Range — 8 Quarters

Analyst Consensus — 4 Analysts

3Buy

1Hold

Consensus RatingBuy# Analysts4Avg. Consensus PT$7Upside to Avg. PT+504.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 30, 2026	HC Wainwright & Co.	Matthew Caufield	Maintained	Neutral	$2
Sep 29, 2026	BTIG	Thomas Shrader	Maintained	Buy	$9
Mar 18, 2026	HC Wainwright & Co.	Matthew Caufield	Downgrade	Buy→Neutral	$10→$2
Nov 10, 2025	BTIG	Thomas Shrader	Maintained	Buy	$9
May 19, 2025	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$10
Apr 7, 2025	BTIG	Thomas Shrader	PT Cut	Buy	$11→$9
Apr 4, 2025	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$10
Mar 3, 2025	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$10
Aug 9, 2024	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$10
Aug 2, 2024	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$10
May 6, 2024	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$10
May 6, 2024	Oppenheimer	Francois Brisebois	Maintained	Outperform	$10
Apr 3, 2024	Oppenheimer	Francois Brisebois	Upgrade	Perform→Outperform	$10
Apr 2, 2024	HC Wainwright & Co.	Matthew Caufield	Reinstates	Buy	$10
Oct 17, 2023	Citigroup	Yigal Nochomovitz	PT Cut	Buy	$25→$8
Oct 17, 2023	Oppenheimer	Justin Kim	Downgrade	Outperform→Perform	—

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Neutral on Aldeyra Therapeutics, Maintains $2 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Neutral and maintains $2 price target.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Aldeyra Therapeutics, Maintains $9 Price Target

BTIG analyst Thomas Shrader reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $9 price target.

Benzinga Newsdesk

This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Analysts downgraded CF, ALDX, TTD, TME and DUOL. Check their ratings and price targets. Interested in TTD? See what analysts say.

Avi Kapoor

PRO
HC Wainwright & Co. Downgrades Aldeyra Therapeutics to Neutral, Lowers Price Target to $2

HC Wainwright & Co. analyst Matthew Caufield downgrades Aldeyra Therapeutics (NASDAQ:ALDX) from Buy to Neutral and lowers the price target from $10 to $2.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Aldeyra Therapeutics, Maintains $9 Price Target

BTIG analyst Thomas Shrader reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $9 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Aldeyra Therapeutics, Maintains $10 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $10 price target.

Benzinga Newsdesk

Aldeyra Therapeutics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Aldeyra Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Neutral on Aldeyra Therapeutics, Maintains $2 Price Target

PRO
BTIG Reiterates Buy on Aldeyra Therapeutics, Maintains $9 Price Target

This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

PRO
HC Wainwright & Co. Downgrades Aldeyra Therapeutics to Neutral, Lowers Price Target to $2

PRO
BTIG Reiterates Buy on Aldeyra Therapeutics, Maintains $9 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Aldeyra Therapeutics, Maintains $10 Price Target

People Also Watch

People Also Watch

Aldeyra Therapeutics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Aldeyra Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Neutral on Aldeyra Therapeutics, Maintains $2 Price Target

PROBTIG Reiterates Buy on Aldeyra Therapeutics, Maintains $9 Price Target

This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

PROHC Wainwright & Co. Downgrades Aldeyra Therapeutics to Neutral, Lowers Price Target to $2

PROBTIG Reiterates Buy on Aldeyra Therapeutics, Maintains $9 Price Target

PROHC Wainwright & Co. Reiterates Buy on Aldeyra Therapeutics, Maintains $10 Price Target

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Neutral on Aldeyra Therapeutics, Maintains $2 Price Target

PRO
BTIG Reiterates Buy on Aldeyra Therapeutics, Maintains $9 Price Target

PRO
HC Wainwright & Co. Downgrades Aldeyra Therapeutics to Neutral, Lowers Price Target to $2

PRO
BTIG Reiterates Buy on Aldeyra Therapeutics, Maintains $9 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Aldeyra Therapeutics, Maintains $10 Price Target